Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial - Université de Lorraine Access content directly
Journal Articles European Journal of Heart Failure Year : 2024

Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

1 Brigham and Women's Hospital [Boston]
2 HMS - Harvard Medical School [Boston]
3 BHF GCRC - British Heart Foundation Glasgow Cardiovascular Research Centre
4 NHCS - National Heart Centre Singapore
5 Duke-NUS Medical School [Singapore]
6 University of Michigan [Ann Arbor]
7 UNIMIB - Università degli Studi di Milano-Bicocca = University of Milano-Bicocca
8 Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy]
9 Feinberg School of Medicine
10 UMCG - University Medical Center Groningen [Groningen]
11 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
12 CIC-P - Centre d'investigation clinique plurithématique Pierre Drouin [Nancy]
13 INI-CRCT - Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy]
14 Cardiovascular & Renal Clinical Trialists - CRCT - French-Clinical Research Infrastructure Network - F-CRIN [Paris]
15 UM - University of Malaya = Universiti Malaya [Kuala Lumpur, Malaisie]
16 Centro de Estudios Clínicos de Querétaro
17 Royal Brisbane and Women's Hospital
18 UQ [All campuses : Brisbane, Dutton Park Gatton, Herston, St Lucia and other locations] - The University of Queensland
19 MHH - Medizinische Hochschule Hannover = Hannover Medical School
20 Beijing Anzhen Hospital
21 CUMS - Capital University of Medical Sciences [Beijing]
22 Taipei Veterans general hospital
23 Université de Médecine Carol Davila
24 Emergency Institute for Cardiovascular Diseases “Prof. Dr. C.C. Iliescu” [Bucharest, Romania]
25 MSH - MAX Superspecialty Hospital [Saket, New Delhi, India]
26 IDIBELL - Institut d'Investigació Biomèdica de Bellvitge = Bellvitge Biomedical Research Institute
27 UB - Universitat de Barcelona
28 NKUA - National and Kapodistrian University of Athens
29 “Attikon” University Hospital
30 EPE - Hospital de S. Francisco Xavier
31 NOVA - Universidade Nova de Lisboa = NOVA University Lisbon
32 Jagiellonian University - Medical College
33 Kaplan Medical Center [Rehovot, Israel]
34 Comenius University in Bratislava
35 Severance Hospital
36 Yonsei University
37 ICCU, National Cardiology Hospital, Bulgaria
38 Saint Luke's Mid America Heart Institute
39 UMKC - University of Missouri [Kansas City]
40 Pauls Stradins Clinical University Hospital, Latvia
41 CUHK - The Chinese University of Hong Kong [Hong Kong]
42 Hospital Group Twente
43 Hospital Cardiologico Aguascalientes
44 MSU - Lomonosov Moscow State University
45 Universidad Nacional de Córdoba [Argentina]
46 IKEM - Institute for Clinical and Experimental Medicine
47 Semmelweis University [Budapest]
48 UniBs - Università degli Studi di Brescia = University of Brescia
49 Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia [Brescia]
50 University of Glasgow
51 Clínica Santa María
52 Instituto de Pesquisa Clínica de Campinas
53 Kawaguchi Cardiovascular and Respiratory Hospital
54 Herlev and Gentofte Hospital
55 Johns Hopkins University School of Medicine [Baltimore]
56 University of Otago [Dunedin, Nouvelle-Zélande]
57 Women's College Hospital and Peter Munk Cardiac Centre
58 TYKS - Turku University Hospital
59 UMN - University of Minnesota System
60 St. Michael's Hospital
61 University of Toronto
62 Medical University of Graz
63 NSC/MDSIC - National Scientific Center "M.D. Strazhesko Institute of Cardiology" [Kyiv, Ukraine]
64 DEÜ - Dokuz Eylül Üniversitesi = Dokuz Eylül University [Izmir]
65 University of Manitoba [Winnipeg]
66 Bayer plc, Research & Development
67 Pharmaceuticals Research & Development, Bayer AG


Aims To describe the baseline characteristics of participants in the FINEARTS‐HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS‐HF trial is comparing the effects of the non‐steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF. Methods and results Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.73 m 2 , elevated natriuretic peptide levels and evidence of structural heart disease were enrolled and randomized to finerenone titrated to a maximum of 40 mg once daily or matching placebo. We validly randomized 6001 patients to finerenone or placebo (mean age 72 ± 10 years, 46% women). The majority were New York Heart Association functional class II (69%). The baseline mean LVEF was 53 ± 8% (range 34–84%); 36% of participants had a LVEF <50% and 64% had a LVEF ≥50%. The median N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) was 1041 (interquartile range 449–1946) pg/ml. A total of 1219 (20%) patients were enrolled during or within 7 days of a worsening HF event, and 3247 (54%) patients were enrolled within 3 months of a worsening HF event. Compared with prior large‐scale HFmrEF/HFpEF trials, FINEARTS‐HF participants were more likely to have recent (within 6 months) HF hospitalization and greater symptoms and functional limitations. Further, concomitant medications included a larger percentage of sodium–glucose cotransporter 2 inhibitors and angiotensin receptor–neprilysin inhibitors than previous trials. Conclusions FINEARTS‐HF has enrolled a broad range of high‐risk patients with HFmrEF and HFpEF. The trial will determine the safety and efficacy of finerenone in this population.
Fichier principal
Vignette du fichier
European J of Heart Fail - 2024 - Solomon - Baseline characteristics of patients with heart failure with mildly reduced or.pdf (1.44 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04578035 , version 1 (16-05-2024)



Scott D Solomon, John W Ostrominski, Muthiah Vaduganathan, Brian Claggett, Pardeep S Jhund, et al.. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial. European Journal of Heart Failure, 2024, ⟨10.1002/ejhf.3266⟩. ⟨hal-04578035⟩
0 View
0 Download



Gmail Mastodon Facebook X LinkedIn More